Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
TruScreen Group Limited is a medical device company specializing in the development, manufacture, and distribution of advanced screening technology for cervical cancer detection. Its primary product is the TruScreen Cervical Cancer screening device, which employs real-time optical and electrical measurements to identify precancerous and cancerous changes in cervical tissue. By integrating AI-enabled diagnostic processes, TruScreen Group contributes to early detection and intervention, thereby aiming to improve patient outcomes in women’s health. The company operates internationally, with notable market activity in New Zealand, China, Mexico, Russia, Vietnam, and Zimbabwe, generating its largest share of revenue from China. As part of the broader healthcare and medical device sector, TruScreen Group’s innovations address critical public health needs, especially in regions lacking widespread access to traditional laboratory-based screening. Its defensive stock type reflects a focus on essential healthcare solutions, making it a significant participant in specialist medical services and health care equipment markets.
